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Many diseases display heterogeneity in clinical features and their progression, indicative of the
existence of disease subtypes. Extracting patterns of disease variable progression for subtypes has
tremendous application in medicine, for example, in early prognosis and personalized medical ther-
apy. This work present a novel, data-driven, network-based Trajectory Clustering (TC) algorithm
for identifying Parkinson’s subtypes based on disease trajectory. Modeling patient-variable inter-
actions as a bipartite network, TC first extracts communities of co-expressing disease variables at
different stages of progression. Then, it identifies Parkinson’s subtypes by clustering similar patient
trajectories that are characterized by severity of disease variables through a multi-layer network.
Determination of trajectory similarity accounts for direct overlaps between trajectories as well as
second-order similarities, i.e., common overlap with a third set of trajectories. This work clusters
trajectories across two types of layers: (a) temporal, and (b) ranges of independent outcome variable
(representative of disease severity), both of which yield four distinct subtypes. The former subtypes
exhibit differences in progression of disease domains (Cognitive, Mental Health etc.), whereas the
latter subtypes exhibit different degrees of progression, i.e., some remain mild, whereas others show
significant deterioration after 5 years. The TC approach is validated through statistical analyses and
consistency of the identified subtypes with medical literature. This generalizable and robust method
can easily be extended to other progressive multi-variate disease datasets, and can effectively assist
in targeted subtype-specific treatment in the field of personalized medicine.
I. INTRODUCTION
The field of network medicine has gained tremendous
traction in recent years. With the growth of public dis-
ease datasets and development in computational meth-
ods, several recent works have attempted to use data-
driven methods to study disease progression [1, 2]. Net-
work medicine [3–6] offers innovative data-driven solu-
tions to disease modeling through analyzing complex
interactions within data. For instance, [6] identifies
disease-related genetic variants through network-based
studies of the human disease network (i.e. the dis-
easeome), in which diseases are linked if they share
one or more associated genes. Functional brain net-
works for neurobiologically relevant graphical proper-
ties of Alzheimers disease are analyzed in [7]. However,
network-based patient subtyping based not only on dis-
ease variable values but also on their trajectories, i.e.,
evolution of variable patterns, is relatively unexplored.
Parkinsons Disease, a degenerative neurological disor-
der, is the second most common neurodegenerative disor-
der following Alzheimers disease, affecting an estimated
7-10 million people worldwide [8]. It is both chronic,
meaning it persists over a long duration, and progressive,
meaning symptoms, such as tremor, loss of memory, im-
paired balance etc. worsen with time [9, 10]. In addition,
it is a highly variable disease, with rate and type of pro-
gression differing significantly across the population [11].
It is increasingly evident that Parkinson’s disease is not
a single entity but rather a heterogeneous disorder with
multiple subtypes. Several studies have attempted to
classify patients into subtypes [12–15].Two recent stud-
ies have developed models of PD progression based on
clinical, demographic and genetic data at baseline, us-
ing hierarchical cluster analysis [16] and a Bayesian mul-
tivariate predictive inference platform [17], to identify
PD subtypes. However, there is no overall consensus
on Parkinson’s subtypes [16], and little is known about
the effect of the interplay between different types of vari-
ables on Parkinson’s progression. Early recognition of pa-
tient subtype allows medical workers to employ subtype-
specific preventive treatment, potentially improving and
prolonging life [18, 19]. However, current approaches in
Parkinson’s subtyping have largely not explored data-
driven analyses to unravel multiple complex influences of
a large number of longitudinal variables on disease pro-
gression [20].
Sophisticated data-driven methods are required to ex-
tract meaningful information effectively from medical
datasets. In recent years, several deep learning ap-
proaches to disease-subtyping have emerged [21, 22].
However, such approaches are limited in extracting in-
terpretable information about the micro-structure of the
subtypes, i.e., the variable relationships that underlie the
subtype. In contrast, network science approaches offer an
intuitive visualization for modeling relationships between
different types of variables. Additionally, evolving inter-
actions between variables are easily represented through
a multi-layer structure.
Significant research has been done in clustering in a
multi-layer network [23, 24]. However, subtyping through
trajectory clustering is relatively unexplored in network
medicine[25, 26]. This work presents a novel multi-
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2layer-network-based Trajectory Clustering (TC) algo-
rithm to identify disease subtypes based on similar-
ities in trajectories through variable clusters. First,
it identifies variable-communities (clusters of variables
that co-express) through modeling patient-variable in-
teractions as a bipartite network. It then tracks
patient-memberships through multiple layers of variable-
communities to define their trajectories. Lastly, disease
subtypes are identified by clustering similar trajectories.
To the best of the author’s knowledge, the only other
work with a trajectory-based approach to Parkinson’s
subtyping [12] does not explore patterns of variable co-
expression at different stages, and consequently does not
define trajectories through a multi-layer network. Addi-
tionally, it does not account for higher order similarities
between trajectories. The contributions of this work are
distinct from and complementary to those in [12].
The contributions of this work are (a) extracting clus-
ters of co-expressing variables at different stages of dis-
ease, and (b) identifying subtypes based on similarities in
disease trajectories. The set of variable clusters identified
by our network are in agreement with Parkinson’s disease
domains recognized in medical literature [27]. Disease
subtypes identified are shown to be statistically distinct
and are supported by the results in [12]. This easily gen-
eralizable approach for multi-layer trajectory clustering
presents a unique way for extracting patterns of disease
progression in complex longitudinal medical data, and
helps bridge the gap between data-based computational
approaches and applied medicine.
II. DATA
Data used in the preparation of this article was ob-
tained from the Parkinsons Progression Markers Initia-
tive (PPMI) database (www.ppmi-info.org/data). It con-
sists of patient variable values across 5 timepoints: base-
line year (denoted as year0) and years-1,2,3, and 4. Upon
excluding patients with incomplete data, 194 patients re-
mained in the analysis.The dataset categorizes the clini-
cal variables into domains (Cognitive, Behavioral, Sleep,
PD Severity, Autonomic, Disability) based upon func-
tionality as shown in 1. Variable data is obtained from
standard medical tests. According to PPMI, motor as-
sessment for variables in this dataset was performed in
a ‘practically defined off’ state, i.e., subjects are asked
to withhold medication prior to the assessment for 12
hours, practically eliminating medication effects on mo-
tor symptoms.
III. NETWORK ARCHITECTURE: STACKED
MULTI-LAYER NETWORK
Variable-communities within each layer are identified
and stacked to create a multi-layer framework across
Domain Variable
Autonomic
 Scales for Outcomes in Parkinson’s Disease - AutonomicSCOPA-AUT / SCOPA
Mental Health
 Geriatric Depression Scale
 State -Trait Anxiety Inventory
GDS
STAI
General PD Severity
 Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) - Part 1
 Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) - Part 2
 Total Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) 
 Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) - Part 3
MDS-UPDRS1 / PD-1
MDS-UPDRS2 / PD-2
MDS-UPDRS3 / PD-3
T-MDS-UPDRS / PD-T
 Epworth Sleepiness Scale
 Rapid Eye Movement Sleep Behavior Disorder Questionnaire
Sleep
RBDQ
ESS
Disability
 Schwab and England Activities of Daily LivingSEADL
Cognitive
 Hopkins Verbal Learning Test
 Benton Judgement of Line Orientation
Letter Number Sequencing
 Montreal Cognitive Assessment
 Symbol Digit Modalities Test
 Semantic Fluency Test
JOLO
SDM
MoCA
HVLT
LNS
SFT
Demographics
AgeAge
FIG. 1: Description of the six medical domains and their
variables in the PPMI clinical dataset.
which which patient trajectories are defined. This pro-
ceeds as follows:
1. Within each layer, individual-variable relationships
for I patients and V relationships, are modeled as
a bipartite network, whose adjacency matrix Z is
created as follows:
• The ‘direction’ of each variable is determined.
If higher variable values indicate greater dis-
ease progression (more severe), then direction
for the vth variable is given by dv = +1, else
direction is dv = −1. For the PPMI clini-
cal data, variables ESS, RBDQ, GDS, STAI,
MDS-UPDRS-1,2,3,T and Age have dv = 1
and HVLT, JOLO, SFT, LNS, SDM, MoCA,
SEADL have dv = −1.
• The value (Fiv) of variable v in individual i is
then converted to a z value, ziv that normal-
izes it between 0 and 1,
ziv =
Fiv −minj∈I Fjv
maxj∈I Fjv −minj∈I Fjv . (1)
• The adjacency matrix Z of size I × V for
the patient-variable bipartite network is pop-
ulated as
Zij =
{
ziv if dv = 1
1− ziv if dv = −1. (2)
2. An independent patient-variable bipartite network
is generated for each layer (an illustrative bipartite
network is shown in in 2 (left)), where a layer could
represent a time-point or a range of outcome vari-
able values. Then Louvain community detection
[28] is implemented on the bipartite network for
each layer l. Louvain community detection yields
the number of communities through optimization
of the Newman-Girvan modularity function [29]
3and has no hyperparameters. It identifies variable-
communities Clk, where k ∈ [0, . . . ,Kl − 1], com-
prising of patients and variables (shown through
shaded ovals in 2 (left)), and Kl is the total num-
ber of variable-communities in layer l.
3. These variable-communities in each layer, variable-
community represented as a node, are stacked
across all layers as shown in Fig. 2(right). This is
the stacked multi-layer graph (G). Each individual
belongs to a variable-community Clk at each time-
point. One can then track individual i membership
over time to define a patient trajectory Ti.
Pa
tie
nt
s Variables
Layer a Layer b Layer c
Stacked Multi-layer NetworkBipartite Network for Layer a
Layer 1 Layer 2 Layer 3
A1
A2
B1 B2
X
Y
cl(X,Y) = 1/3
cl(X,Y) = 1/3
C11
C12
C13
A1
A2
B1 B2
X
Y
FIG. 2: (left) shows a representative bipartite patient-variable
network for one layer. The highlighted ovals represent
variable-communitites consisting of patients and disease vari-
ables. (right) represents a stacked multi-layer graph over
three layers, where the variable-communities from (left) form
the first layer. Three sample trajectories are drawn, and the
corresponding closeness between nodes X and Y is calculated.
The TC algorithm to cluster patient trajectories (and
hence patients) is presented in sec. IV.
IV. TRAJECTORY CLUSTERING ALGORITHM
Each node in G is a variable-community. The Tra-
jectory Clustering (TC) algorithm identifies patient sub-
types based by clustering patients with similar trajec-
tories of disease progression on the stacked multi-layer
network G as follows:
1. ‘Node closeness’ cl(X,Y ) between two nodes X and
Y in graph G is defined as the fraction of whole or
partial trajectories passing through X and Y that
overlap. Suppose A and B are sets of all edges
(both inter-layer and intra-layer), with repetition,
that belong to trajectories passing through node
X and node Y respectively, then node closeness
between is defined as
cl(X,Y ) =
#(A ∩B)
#(A ∪B) . (3)
where # denotes the size of a set. Note that
cl(X,X) = 1. Fig. 2 (b) presents a simple exam-
ple of node closeness calculated between nodes X
and Y . There is one overlapping edge-pair A2, B2
on trajectories passing through nodesX,Y , and the
total size of the set of edges on these trajectories is
3. Hence, cl(X,Y ) = 1/3.
2. Trajectory Similarity (η) between two individual
(patient) trajectories Ti and Tj is then given by
Σtcl(X(t)Ti , Y (t)Tj ), where X(t)Ti is the node X(t)
that trajectory Ti passes through at timepoint t.
3. A patient-patient network P is created whose ad-
jacency matrix is given by
Pi,j = η(Ti, Tj). (4)
.
4. Louvain community detection is implemented
on the network P to identify M trajectory-
communities Sk where k ∈ [0, . . .M − 1] with sim-
ilar disease progression trajectories.
Calculating η through node closeness accounts for
second-order relations between trajectories, i.e., interac-
tions between two trajectories without overlap that result
from their overlap with a third set of trajectories. Im-
portant properties of the second-order TC algorithm are
outlined in Appendix A.
V. RESULTS
A. Bipartite variable-communities
Upon creating an individual-variable network for each
layer (where each layer is a timepoint) as in III, Louvain
community detection is performed on each layer. Figure
3 shows the communities Cl identified in each layer l com-
prising of individuals as well as dominant variable. These
variable-communities are characterized by the dominant
disease variables that belong to them (listed above each
variable-community in Fig. 3).
The variable-communities are indicative of sets of vari-
ables that patients co-express with high severity in dif-
ferent stages of the disease. For instance, the last panel
(bottom row) in the baseline year indicates that in early
stages of disease, patients displaying severity in variable
GDS for instance, are also likely to display severity in
STAI. While variables are treated independently in this
analysis, the emergent variable-community structure is
largely consistent with domain structure in medical lit-
erature [27]. The composition of variable-communities
remains similar across the layers. Age and JOLO (a cog-
nitive variable) cluster together in all layers. Another
variable-community comprises of all the other cognitive
variables. Disability (SEADL) and General PD Sever-
ity Variables (PD-1,2,3,T) commonly co-express with
high severity together in all layers except in the base-
line year where PD-1 is found to co-express with Auto-
nomic (SCOPA-AUT) and Sleep (RBDQ) variables. As
4Baseline Year1 Year2 Year3 Year4
Layers
FIG. 3: Community profiles of the variable-communities in each layer. Here, the layers represent time-points. Each panel rep-
resents one variable-community comprising of individuals and variables. These communities are characterized by the variables
in them, that are listed above each panel. The panels show the average z value of all people in that variable-community, and
error bars are given by their standard deviation.
General PD Severity variables represent motor function-
ing, their co-occurence with disability is expected. Sleep
and Autonomic variables often clustered together in sev-
eral layers. Mental Health variables (GDS, STAI) are
initially form an independent variable-community, how-
ever, as time progresses, they co-express with high sever-
ity with PD Severity and Disability domains. Deteriora-
tion of mental health is expected with worsening motor
skills and increased disability, particularly in later stages
of disease progression. The clustering of variables in the
same domain is further validation of our method yielding
medically relevant results. The individuals within each
variable-community have relatively high average severity
of corresponding variables that characterize the commu-
nity.
1. Statistical analysis
The Kruskal-Wallis statistical test [30] is an estimate of
whether two variables are sampled from the same distri-
bution. Kruskal-Wallis test for multiple groups was con-
ducted to validate this approach and demonstrate some
of the differences between variable-communities. This
test was chosen because values for several of the vari-
ables did not follow a normal distribution.
Table I tabulates the medians and the p-values of the
Kruskal-Wallis statistical test applied to each layer. Me-
dians are calculated from the whole population raw data.
Variables with negative directions are denoted by an as-
terisk (*). Comparisons not meeting the criteria for sta-
tistical significance are shown in bold text. The p-values
are a measure of statistical differences amongst the vari-
able values of the individuals belonging to the differ-
ent variable-communities. A majority of the p-values
are below the significance level of α = 0.05, suggesting
that there an underlying statistical difference between
the variable distributions in the variable-communitites
in a layer.
B. Trajectory Clustering on Temporally Stacked
Multi-layer Network
1. Trajectory communities
Each individual is a member of one of the variable-
communities at each time-point (or in each layer in this
case). Tracing their membership yields their trajectory.
The TC algorithm (sec. III) identifies patient subtypes
based on similarities in their trajectories through the
multi-layer network.
As shown in Fig. 4, the TC algorithm identifies four
distinct trajectory-communities (subtypes) for disease
progression across temporal layers. The edges are di-
rected from left to right (baseline year to year4), shown
without arrows for ease of viewing. The thickness of the
edges is a measure of the flow of people between the cor-
responding variable-community nodes. Thus, edge thick-
ness is an estimate of the probability of transition of pa-
tients expressing high severity from one variable set to
another as time progresses.
5TABLE I: Comparing the variable-communities (described in Fig. 3) in each layers (representative of timepoints) through the
Kruskal-Wallis p-values.
Variable Median Year0 Year1 Year2 Year3 Year4
Age 71.00 1.759E-08 2.439E-07 2.263E-09 2.966E-06 5.115E-08
Cognitive
JOLO* 14.00 3.687E-06 6.807E-06 8.491E-05 2.769E-03 1.526E-09
SDM* 42.00 3.951E-07 3.764E-09 7.653E-07 5.050E-08 7.435E-12
SFT* 47.50 5.151E-07 1.920E-06 1.381E-04 3.276E-09 2.753E-07
HVLT* 0.90 3.222E-03 6.110E-07 5.731E-03 2.959E-01 7.282E-05
LNS* 11.00 1.207E-05 1.457E-08 1.347E-07 1.234E-11 5.982E-11
MOCA* 27.00 1.767E-05 3.470E-05 1.163E-06 2.379E-04 2.928E-08
Other
SEADL* 95.00 4.317E-10 5.634E-10 1.039E-07 6.277E-07 3.821E-08
RBDQ 4.00 2.931E-08 1.247E-06 1.212E-09 2.699E-10 1.172E-11
ESS 6.00 1.265E-01 6.166E-08 6.262E-08 4.623E-10 1.191E-08
SCOPA-AUT 9.00 6.022E-09 4.087E-07 5.470E-10 8.695E-09 2.638E-10
GDS 2.00 6.678E-06 1.323E-08 7.281E-05 2.941E-08 9.002E-09
STAI 65.00 1.805E-07 4.617E-09 1.374E-03 6.388E-07 2.223E-08
General PD
PD-1 5.50 3.609E-10 8.432E-09 1.789E-09 3.372E-12 4.205E-12
PD-2 5.00 1.471E-08 1.969E-09 1.231E-08 1.599E-12 2.570E-15
PD-3 20.00 2.587E-08 1.088E-08 1.026E-10 2.275E-09 4.794E-12
PD-T 32.00 1.674E-14 5.236E-14 1.280E-14 9.158E-16 5.981E-17
The green subtype S0 with 56 patients is characterized
by an older population and higher severity of JOLO, as
well as increase in general Cognitive impairment as time
progresses. The orange subtype S1 with 55 patients dis-
plays high values of Cognitive variables. In addition, it
progresses to high severity in General PD Severity and
Sleep variables. The red subtype S2 with 53 patients is
characterized by high Disability and severe General PD
(motor), and develops severity in Mental Health variables
through progression of time. Lastly, the blue subtype S3,
the smallest trajectory-community with 33 patients, is
characterized by severe Autonomic and Sleep variables.
It shows limited Cognitive and General PD severity in
earlier years, and the severity of expression of these vari-
ables reduces over time.
2. Trajectory-community profiles
Figure 5 shows the trajectory profile (weighted av-
erage profile of all individuals belonging to a trajectory-
community) across all layers (which is equivalent to time-
points in this case). The trajectory profiles (Sti ) of
trajectory-community i at timepoint t is obtained by
taking the weighted average of the variable-communities
that members of the trajectory-community belong to as
follows:
Sti =
ΣiX(t)Ti
κti
. (5)
where i ∈ κti and κti is the total number of individuals
in trajectory-community Si and layer t. X(t)Ti is the
variable-community that individual i belongs to at time
t. As seen in Fig. 5, each trajectory-community has a
distinct trajectory profile with different evolution pat-
terns and high values of their corresponding dominant
variables.
The green trajectory-community S0 with 56 members
has a relatively mild disease stage, inspite of having a
relatively older population. Disability, Autonomic, and
General PD severity start very low, and continue to stay
low over time. Amongst the cognitive variables, JOLO
is slightly higher than in other trajectory-communities
through the layers, ESS starts high and reduces over
time, whereas HVLT gets more severe. The orange
trajectory-community S1 with 55 members show con-
sistently high severity in all Cognitive variables except
JOLO and MoCA. Other variables are low; Disability
reduces across the layers, whereas Sleep variables show
a slight increase as disease progresses across time. The
red trajectory-community S2 with 53 members has rel-
atively severe General PD Severity motor variables. As
time progresses, Autonomic, Mental Health and Disabil-
ity demonstrate growth in severity. Lastly, the blue
trajectory-community S3, the smallest with 33 members
show heterogeneity in the variable structure. General PD
Severity variables remain consistently low through time,
whereas Sleep variables RBDQ and ESS show growth in
severity across the layers.
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JOLO
ESS
SDM
SFT
HVLT
LNS
MOCA
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PD-2
PD-3
PD-T
RBDQ
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RBDQ
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PD-1
PD-2
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PD-T
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Age
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Age
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STAI
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PD-3
PD-T
RBDQ
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Age
JOLO
SDM
SFT
HVLT
LNS
MOCA
SEADL
GDS
STAI
PD-1
PD-2
PD-3
PD-T
RBDQ
ESS
SCOPA
Baseline Year1 Year2 Year3 Year4
Layers
Cognitive
Disability
Sleep
Autonomic
Mental 
Health
Domains
General 
PD 
Severity
Variables
JOLO

SDM  

SFT    

HVLT  

LNS    

MOCA 

SEADL

RBDQ

ESS 
SCOPA

GDS

STAI
PD-1

PD-2

PD-3

PD-T
Age
Color Trajectory 
Community
S0
S1
S2
S3
FIG. 4: Each node represents a variable-community consisting of variables and patients. The size of the node denotes the
number of people in the variable-community. The variables are color-coded by domain. Patient trajectories from the baseline
layer to the year4 layer are clustered using the TC algorithm. The trajectory-communities (subtypes) are color-coded and
directed (from left to right). The thickness of a colored edge denotes the number of patients flowing along that edge in the
corresponding trajectory-community. Number of people in each subtype are as follows: green - 56, orange - 55, red - 53, blue -
33. Edges with fewer than 3 people are not plotted.
3. Statistical analysis
To validate the algorithm and demonstrate the dif-
ferences in the progression of the different trajectory-
communities, the Kruskal-Wallis statistical test for multi-
ple groups was conducted on the difference between the
consecutive year variable values. This test was chosen
because values for several of the variables violated the
normality assumption.
Table II tabulates the medians and the p-values of
the Kruskall-Wallis statistical test to study statistical
differences in the growth of variables across layers be-
tween individuals belonging to the different variable-
communities. Variables with negative directions are de-
noted by an asterisk (*). Comparisons that do not meet
the significance criteria are highlighted in bold in the
table. All but two of the p-values are below the signifi-
cance level of α = 0.05, suggesting that there exist sig-
nificant differences in variable progression of the different
trajectory-communities.
C. Trajectory Clustering Across an Independent
Outcome Variable
Often, medical practitioners may be interested in
studying the evolution of disease variables as a function
of an outcome variable (a clinical test or variable known
to be indicative of disease progression). Defining layers
through values of an outcome variable, allows us to iden-
tify subtypes based on trajectories through progression
of an outcome variable.
MDS-UPDRS-3 (divided into quartiles on the x axis)
is known to be indicative of PD progression and was cho-
sen as the outcome variable. In Fig. 6, three disease
7Baseline
Year1
Year2
Year3
Year4
Trajectory Communities
FIG. 5: Trajectory profiles of the 4 trajectory-communities. The ith vertical set of panels corresponds to a trajectory-community
denoted by Si). Within each column, the five panels arranged from top to bottom show the average profile in years 0(base-
line),1,2,3,4 respectively. Each individual panel shows the average z values across all variables of κli patients in a trajectory-
community.
progression trajectory-subtypes across outcome variable
layers are identified. The layers are defined by raw base-
line MDS-UPDRS-3 values as follows: layer low contains
values below 22.0, layer low-mid contains values between
22.0 and 31.0, layer mid-high contains values between
31.0 and 38.0, and layer high contains values above 38.0.
Dependent variables are chosen to be the same as in sec-
tion A, with the exception of General PD severity vari-
ables. This method is generalizable to selection of any
outcome variable. Fig. 6, the size of the nodes indicate
the number of patient-years in that variable-community,
i.e., one patient may contribute up to 5 times to a certain
community, one for each timepoint. This implies that a
patient may, in consecutive years, remain in the same
variable-community, or transition to a different variable-
community in the same layer, or transition to a different
variable-community in a different layer.
Fig. 7(a) shows the variable-community profile, i.e., av-
erage z values of all the patients in each community in
each layer with errors given by their standard deviation.
The position of variable-community profiles corresponds
to the node in Fig. 6. In Fig. 7(a), one can see that
the variables denoting a variable-community have a cor-
respondingly higher relative z value. In Fig. 7(b) shows
the average trajectory profile as calculated in 5 amongst
for each trajectory-community across each layer.
As seen in Fig. 6 and Fig. 7(b),The green trajectory-
community S0 with 47 patients largely remains in low to
low-medium PD-3 layers, with 101 patient-years in layer
low, and 72 patient-years in layer low-medium. Individ-
uals in this trajectory-community start with low disease
state (as measured by PD-3), and show slow disease pro-
gression over the years, staying in the low-medium range
of disease progression. The orange trajectory-community
S1 with 44 patient-years is the least affected. Patients are
most severely affected in the Cognitive domain, however
they remain largely in the low disease layer. The red
trajectory-community S2 with 58 starts in a relatively
high disease state, and consistently gets worse, whereas
the blue trajectory-community S3 with 48 starts rela-
tively healthy but with severe disease progression into
mid-high and high layers of disease severity measured
through PD-3.
VI. CONCLUSION
This work introduces a novel algorithm for the identifi-
cation of subtypes based on relationships between trajec-
tories through a multi-layer network. Multidimensional
clinical datasets are often not used to their full potential
due to the complexities of a cohesive analysis. This work
extracts disease variables that co-express with high sever-
ity at different stages of disease progression. Then it ex-
tracts trajectories of progression through these variable-
communities, i.e., through sets of high severity variables.
Lastly, it identifies disease subtypes through clustering
patient trajectories. Additionally, it promotes second-
order comparisons in the calculation of η i.e., correlations
across time between two trajectories that do not have
overlapping edges but interact with common neighbor-
ing trajectories. The agreement of variable-clusters with
the domain-structure e.g. Cognitive, Autonomic etc., as
well as the statistical analysis, both validate the success
of this approach.
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FIG. 6: Trajectory clustering across the outcome variable - baseline MDS-UPDRS3 / PD3 values. The layers represent quartiles
of the outcome variable raw values. The boundary values that determine the layers are denoted in red. Each node represents a
variable-community consisting of variables and patients. The size of the node denotes the number of patient-years associated
with the community. Each patient can contribute upto 5 times (one for each year) to a variable-community. The variables are
color-coded by domain in the legend. Patient trajectories directed from the baseline year to the year4 are clustered using the
TC algorithm. These trajectories progress in time and hence, are not required to pass through all the outcome variable layers.
The trajectory-communities (subtypes) are color-coded. The thickness of a colored edge denotes the number of patients along
that edge in the corresponding trajectory-community. Number of people in each trajectory-community are as follows: green -
47, orange - 44, red - 58, blue - 48.
Parkinson’s Disease has a multitude of clinical vari-
ables that interact in complex manners that vary through
stages of the disease. A number of studies have identi-
fied Parkinson’s subtypes based on baseline characteris-
tics [16, 31, 32]. In contrast, our novel algorithm uses
longitudinal data (or patient trajectory over time) to
identify disease subtypes through TC. In other words,
our method accounts for both disease variable values as
well as their progression patterns as a patient progresses
through the different layers of the multi-layer stacked-
bipartite network. While Parkinson’s Disease, being both
multivariate and progressive, served to demonstrate the
effectiveness of the TC algorithm, the algorithm can, in
principle, be easily extended to include non-clinical fea-
tures, such as genetic or fluid biomarkers, as well as to
other datasets.
The TC algorithm identifies subtypes through cluster-
ing patient trajectories across layers. This work presents
two methods of analysis and visualization of disease pro-
gression: Parkinson’s disease trajectory through time,
and Parkinson’s disease trajectory through an outcome
variable (representative of disease progression). Our
second-order TC algorithm emphasizes the dynamical as-
pect of disease progression in addition to the static prop-
erties of the associated variables at every stage, contrary
to several earlier data-driven methods in medicine that
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FIG. 7: (a) Variable-community profiles in each layer. Here, the layers represent values of the outcome variable MDS-UPDRS-3.
Each panel represents a variable-community comprising of patient-years and variables. The variables in each variable-community
are listed above each panel, and are used to identify the variable-communities. The panels show the average z value of all
patient-years in that variable-community. (b)Trajectory profiles of the 4 trajectory-communities. The ith vertical set of panels
corresponds to a trajectory community Si. Within each column, the four panels arranged from top to bottom show the average
profile in layers low, low-mid, mid-high, and high. Each individual panel shows the average z values across all variables of κ
patient-years in a trajectory-community in a layer. All error bars are given by the standard deviation.
emphasize one or the other. Results are presented in an
interpretable visualization that is easily accessible to and
comprehensible by medical practitioners in contrast with
black box methods in machine learning.
The TC algorithm is a data-driven network-based
method for detection of patient subtype. Like other data-
driven methods, this analysis is limited by the availability
and quality of data. As larger datasets are made avail-
able, such results are likely to be more informative and
robust. Additionally, in applying a data-driven approach
to medical data, important medical decisions must al-
ways be made in conjunction with medical expertise.
An advantage as well as caveat of this approach is that
trajectories are tracked through variable sets, and not
through individual variables. Future directions of such
work would naturally include extension to other types
of medical data (genetic [33], biomarker etc.), as well as
extension to other types of time-evolving and heteroge-
nous datasets. Additional directions of potential inter-
est include studying disease evolution through other out-
come variables, as well as treatment-based modifications
to the algorithm where effects of treatment are expected
during gathering of data. By the nature of such a data-
driven method, this approach may not be appropriate for
datasets with high variability, low quantity, or data with
inconsistent temporal sampling.
Parkinson’s disease is a highly variable disease with a
long onset time. Knowledge of which cluster a new pa-
tient belongs to in the baseline year, would allow medical
practitioners to predict their subtype and corresponding
trajectory, including the type and rate of disease pro-
gression. This could open up new and exciting avenues
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TABLE II: Comparing evolution of trajectory-communities
by calculating the Kruskal-Wallis p-values for variable differ-
ences between consecutive years.
Variable Year1-Year0 Year2-Year1 Year3-Year2
Age 6.777E-02 3.636E-07 1.684E-07
Cognitive
JOLO* 1.451E-06 7.295E-04 3.335E-11
SDM* 2.579E-05 2.556E-02 6.247E-05
SFT* 2.089E-05 9.683E-07 1.005E-05
HVLT* 4.225E-04 1.892E-05 1.548E-18
LNS* 3.724E-06 8.711E-02 3.486E-04
MOCA* 2.562E-04 5.158E-07 3.142E-13
Other
SEADL* 1.092E-02 1.809E-07 5.618E-08
RBDQ 9.470E-04 3.796E-09 2.015E-02
ESS 6.881E-15 1.059E-07 1.708E-04
SCOPA-AUT 3.035E-03 1.202E-05 3.529E-11
GDS 4.778E-08 6.070E-03 4.111E-05
STAI 3.209E-07 4.996E-02 2.330E-05
General PD
MDS-UPDRS-1 3.648E-03 2.545E-05 2.418E-02
MDS-UPDRS-2 6.627E-03 3.092E-04 2.503E-03
MDS-UPDRS-3 2.502E-03 1.405E-07 2.590E-06
T-MDS-UPDRS 9.561E-03 2.809E-04 3.607E-03
in the field of personalized medicine. Moreover, predic-
tion of disease progression will improve prognostic coun-
seling, a problem commonly encountered by clinicians,
by highlighting predicted disease features. It will also
support them in seeking more aggressive treatment for
patients predicted to display rapid disease progression.
Thus, this multi-layer network-based TC approach har-
nesses data to provide interpretable solutions in the field
of early, predictive medicine.
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Appendix A: Properties of second-order Trajectory
Clustering
The second-order TC algorithm satisfies three impor-
tant properties:
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FIG. 8: (a), (b), (c) and (d) are examples of three different
trajectories (black, green, blue) going across a temporal net-
work. Each of the nodes represent a variable-community and
layers across the x-axis represent time. At each timepoint,
there are two variable-communities (A,B), (C,D), (E,F) and
(G,H) respectively.
1. Summation: Multiple trajectory pairs with over-
lapping edges passing through the same node pair
reinforce node closeness between them. For in-
stance, consider nodes A and B in Fig. 8(a). Tra-
jectories Tblack and Tblue (blue) have two overlap-
ping edges C − E and E −G. Additionally, Tblack
and Tgreen also have the same overlapping edge
E −G. Hence, cl(A,B) ∝ 3, and each overlapping
trajectory-pair contributes to the corresponding
trajectory similarities. Comparing Fig. 8 (a),(b),
and (c) yields cl(A,B)a > cl(A,B)b > cl(A,B)c,
where the subscript denotes the panel.
2. Temporal Independence: The algorithm weighs all
edges equally. An overlapping edge from layer T0
to layer T1 has the same weight as an overlapping
edge from layer T1 to layer T2.
3. Temporal Equivalence: Trajectory similarity η is
calculated based on future as well as past overlap
of trajectory pairs. For instance, in Fig. 8(d), tra-
jectories passing through C and D have exactly one
overlapping edge (edge E−G traversed by the black
and blue trajectories in the ‘future’, i.e., after the
trajectories pass through nodes C and D respec-
tively). Now, nodes E and F also have exactly one
overlapping edge (edge A−Ctraversed by the black
and green trajectories in the ‘past’, i.e., before the
trajectories pass through nodes E and F respec-
tively). However, cl(C,D) = cl(E,F ), i.e., node
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closeness is independent of the temporal-occurrence
of the overlap.
These properties ensure that node closeness, and hence
trajectory similarity, as described in the main text is
truly representative of the second-order similarity be-
tween patient profiles, and that similarities in disease
progression at all timepoints are equally considered.
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